Cite
364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC.
MLA
Mezquita, L., et al. “364OClinical Utility of CtDNA Genomic Alterations (GA) Based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) in Advanced NSCLC.” Annals of Oncology, vol. 30, Nov. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz431.001.
APA
Mezquita, L., Planchard, D., Suarez, M. D., Aldea, M., Naltet, C., Lamberts, V., Grecea, M., Martin-Romano, P., Kievit, F. de, Jovelet, C., Lacroix, L., Masip, J. R., Lavaud, P., Gazzah, A., Morris, C., Howarth, K., Green, E., Vassal, G., Massard, C., & Besse, B. (2019). 364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz431.001
Chicago
Mezquita, L, D Planchard, M Dorta Suarez, M Aldea, C Naltet, V Lamberts, M Grecea, et al. 2019. “364OClinical Utility of CtDNA Genomic Alterations (GA) Based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) in Advanced NSCLC.” Annals of Oncology 30 (November): N.PAG. doi:10.1093/annonc/mdz431.001.